Oral anticoagulants and chronic kidney disease (literature review)

Morozov Iu.A.; Charnaia M.A.; Isaeva A.M.

doi:https://doi.org/

Morozov Iu.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Charnaia M.A.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Isaeva A.M.

RNTsKh im. akad. B.V. Petrovskogo RAMN, Moskva

Oral anticoagulants and chronic kidney disease (literature review)

Authors:

Morozov Iu.A., Charnaia M.A., Isaeva A.M.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2014;7(6): 92‑95

Read: 24949 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Morozov IuA, Charnaia MA, Isaeva AM. Oral anticoagulants and chronic kidney disease (literature review). Russian Journal of Cardiology and Cardiovascular Surgery. 2014;7(6):92‑95. (In Russ.)

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)

Использование инфографики авторами научных работ

References:

Charnaia M.A., Morozov Iu.A. Trombozy v klinicheskoĭ praktike. M GéOTAR-Media 2009.
Abe M., Maruyama N., Suzuki H. et al. International normalized ratio decreases after hemodialysis treatment in patients treated with warfarin. J Cardiovasc Pharmacol 2012; 60: 502-507.
Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 12: 1139-1151.
Eikelboom J.W., Weitz J.I. New anticoagulants. Circulation 2010; 121: 13: 1523-1532.
Elliott M.J., Zimmerman D., Holden R.M. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007; 50: 433-440.
Fox K.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 19: 2387-2394.
Gompou A., Griveas I., Kyritsis I. et al. INR deviations in hemodialyzed patients under low dose oral anticoagulant therapy. Inter J Artif Org 2009; 32: 10: 752-755.
Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 11: 981-992.
Hallan S.I., Coresh J., Astor B.C. et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006; 17: 8: 2275-2284.
Hart R.G., Eikelboom J.W., Ingram A.J., Herzog C.A. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012; 8: 569-578.
Heidbuchell H., Verhammel P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 5: 625-651.
Levine M.N., Raskob G., Landefeld S., Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995; 108: 4: 276S-290S.
Limdi N.A., Beasley T.M., Baird M.F. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20: 912-921.
Maruyama N., Abe M., Okada K. et al. Changes to prothrombin international normalized ratio in patients receiving hemodialysis. Inter J Clin Pharmacol Therap 2013; 51: 283-287.
Melloni C., Peterson E.D., Chen A.Y. et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2008; 51: 991-996.
Roberts G.W., Ibsen P.M., Schioler C.T. Modified diet in renal disease method overestimates renal function in selected elderly patients. Age Ageing 2009; 38: 698-703.
Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant 2000; 15: 2: 156-160.
Schulman S., Crowther M.A. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016-3023.
Spyropoulos A.C., Douketis J.D. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120: 2954-2962.
Van Ryn J., Standier J., Liesenfeld K.-H. et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombol Haemost 2010; 103: 1116-1127.
Wetmore J.B., Mahnken J.D., Rigler S.K. et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int 2012; 81: 5: 469-476.
Winkelmayer W.C., Liu J., Setoguchi S., Choudry N.K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with atrial fibrillation. Clin J Am Soc Nephrol - 2011; 6: 2662-2668.
Wizemann V., Tong L., Satayathum S. et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010; 77: 12: 1098-1106.
Zacchigna M., di Luca G., Cateni F., Maurich V. Improvement of warfarin biopharmaceutics by conjugation with poly(ethylene glycol). Eur J Pharmacol Sci 2004; 23: 4-5: 379-384.